Skip to content

Everfront Biotech Inc.

關於長弘
- 創辦人的話
新藥開發
- EF-001 | 治療高度惡性腦瘤
- EF-009 | 治療胰臟癌
智慧財產
最新消息
聯絡我們
HOME 🇺🇸
About EFB 🇺🇸
Pipelines 🇺🇸
- EF-001
- EF-009

關於長弘

關於長弘

2019-08-222022-06-08 jacky

　　長弘生物科技股份有限公司在總裁陳和錦

EN NEWS

Local delivery therapy of Cerebraca® Wafer being highlighted in the natural review
2022-06-27
Case report – Cerebraca® Wafer implantation combined with CIK therapy for the treatment of recurrent Glioblastoma revealed superior clinical outcome (overall survival extended for more than 24 months).
2022-06-27
Case report – Cerebraca® Wafer implantation for the treatment of un-resectable cervical spine Glioblastoma resulted in the tumor regression.
2022-06-27
Outstanding clinical outcomes were published in various journals. We have listed as follows:
2022-06-27

長弘生物科技鎖定未被滿足的醫療需求。

致力開發孤兒藥，以治療世上最致命的病症。

Everfront Biotech Inc. is committed to fulfilling unmet medical needs by developing orphan drugs to treat the world’s most lethal diseases.

與我們聯絡：

研發暨臨床醫學研究中心

Research, Development and Clinical Medical Research Center

🏢地址：

974花蓮縣壽豐鄉大學路二段1號974國立東華大學創新育成中心1之10室

NDHU IIIC R1-10, No.1, Sec.2, Da Hsueh Rd., Shoufeng, Hualien 974, Taiwan (R.O.C.)

☎電話：

+886-3-8630108

📧email

efbiotech@efbiotech.com

台北營運總部

Corporate Headquarters

🏢地址：

103台北市大同區重慶北路二段178-3號2樓

2F, No.178-3, Sec.2, Chongqing N. Rd., Datong Dist., Taipei City 103 , Taiwan (R.O.C.)

☎電話：

Copyright © 2023 Everfront Biotech Inc.. All rights reserved.
Theme: ColorMag by ThemeGrill. Powered by WordPress.